- Home
- VRTS vs SNDX Comparison
VRTS vs SNDX Comparison
Compare VRTS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTS
- SNDX
- Stock Information
- Founded
- VRTS 1988
- SNDX 2005
- Country
- VRTS United States
- SNDX United States
- Employees
- VRTS N/A
- SNDX N/A
- Industry
- VRTS Investment Managers
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- VRTS Finance
- SNDX Health Care
- Exchange
- VRTS Nasdaq
- SNDX Nasdaq
- Market Cap
- VRTS 1.3B
- SNDX 1.2B
- IPO Year
- VRTS 1992
- SNDX 2016
- Fundamental
- Price
- VRTS $173.79
- SNDX $12.01
- Analyst Decision
- VRTS Hold
- SNDX Strong Buy
- Analyst Count
- VRTS 4
- SNDX 10
- Target Price
- VRTS $225.75
- SNDX $36.20
- AVG Volume (30 Days)
- VRTS 47.7K
- SNDX 1.6M
- Earning Date
- VRTS 04-25-2025
- SNDX 03-03-2025
- Dividend Yield
- VRTS 5.17%
- SNDX N/A
- EPS Growth
- VRTS N/A
- SNDX N/A
- EPS
- VRTS 16.89
- SNDX N/A
- Revenue
- VRTS $906,949,000.00
- SNDX $23,680,000.00
- Revenue This Year
- VRTS N/A
- SNDX $274.86
- Revenue Next Year
- VRTS $3.20
- SNDX $130.47
- P/E Ratio
- VRTS $10.30
- SNDX N/A
- Revenue Growth
- VRTS 7.30
- SNDX N/A
- 52 Week Low
- VRTS $167.13
- SNDX $11.63
- 52 Week High
- VRTS $252.82
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- VRTS 41.72
- SNDX 35.22
- Support Level
- VRTS $169.00
- SNDX $12.70
- Resistance Level
- VRTS $180.92
- SNDX $13.80
- Average True Range (ATR)
- VRTS 4.89
- SNDX 0.67
- MACD
- VRTS 0.59
- SNDX -0.08
- Stochastic Oscillator
- VRTS 48.30
- SNDX 14.45
About VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to individuals and institutions. Its retail products include open-end mutual funds, closed-end funds, exchange-traded funds, and variable insurance funds. Geographically, the activities are carried out through the region of the U.S. and the group generates revenue through investment management fees, distribution and service fees and administration and shareholder service fees.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.